A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

Journal of Infectious Diseases

Volumn 194, Issue 1, 2006, Pages 20-28

  Cozzi Lepri, Alessandro ^a   De Luca, Andrea ^b   Phillips, Andrew N ^b   Bongiovanni, Marco ^b   Di Giambenedetto, Simona ^b   Mena, Maurizio ^b   Moioli, Maria Cristina ^b   Arlotti, Massimo ^b   Sighinolfi, Laura ^b   Narciso, Pasquale ^b   Lichtner, Miriam ^b   Cauda, Roberto ^b   D'Arminio Monforte, Antonella ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EXPERIENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HISTORY, 21ST CENTURY; HUMANS; LIPIDS; MALE; MIDDLE AGED; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; VIRAL LOAD;

EID: 33745225008     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504265     Document Type: Article

References (50)

1. Phillips AN, Staszewski S, Lampe F, et al. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186:1086-91.
2. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160:1123-32.
3. Staszewski S, Miller V, Sabin CA, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13:367-73.
4. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1 infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-9.
5. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in HIV infection. J Infect Dis 2002; 185:1251-60.
6. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17:1741-51.
7. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15:1517-26.
8. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-14.
9. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long term response to therapy. AIDS 1998; 12:1619-24.
10. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15:2379-84.
11. Lampe FC, Johnson MA, Lipman M, et al. Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. AIDS 2003; 17:768-70.
12. Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to CART. Antivir Ther 2004; 9:291-6.
13. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-9.
14. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther 2003; 8:585-94.
15. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28:232-9.
16. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with HIV infection and long-lasting suppression. Clin Infect Dis 2002; 34:504-10.
17. Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful CART to trizivir: 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4:79-86.
18. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-46.
19. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease-inhibitor-experienced patients with HIV-associated lipodystrophy. JAIDS 2001; 27:229-36.
20. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14:807-12.
21. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
22. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-46.
23. Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003; 37:41-9.
24. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. JAIDS 2001; 27:350-64.
25. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001; 15:1133-42.
26. Dieleman JP, Sturkenboom MCJM, Wit FW, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among HIV-infected patients with virus suppression. J Infect Dis 2002; 185:1261-8.
27. Moyle GJ, Gazzard BG. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS 2002; 16:1086-7.
28. Chiesa E, Bini T, Adorni F, et al. Simplifications of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther 2003; 8:27-35.
29. Hirschel B, Flepp M, Bucher HC, et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002; 16:381-5.
30. Smith CJ, Phillips AN, Hill T, et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005; 192:1387-97.
31. Phillips AN, Ledergerber B, Horban A, et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004; 18:1795-804.
32. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17:2451-9.
33. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. AIDS 2000; 14:499-507.
34. De Luca A, Vendittelli M, Baldini F, et al. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. Antivir Ther 2004; 9:583-93.
35. d'Arminio Monforte A, Testori V, Adorni F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999; 13:1669-76.
36. National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. National Heart, Lung, and Blood Institute, National Institutes of Health. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full. pdf. Accessed 1 May 2006.
37. Gulick RM, Ribaudo H, Kuritzkes D, for the ACTG A5095 Team. Triple-nucleoside regimens versus efavirenz [comment]. N Engl J Med 2004; 351:718-9.
38. Moyle GJ. The impact of abacavir on lipids and lipodystrophy. AIDS Read 2005; 15:62-6.
39. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
40. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-15.
41. Molina JM, Chene G, Ferchal F, et al. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J Infect Dis 1999; 180:351-8.
42. Amin J, Moore A, Carr A, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003; 4:252-61.
43. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003;4(Suppl 1):1-41.
44. Phillips AN, Grabar S, Tassie J-M, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection; comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13:2075-82.
45. Sabin CA. The role of observational studies in assessing the impact of antiviral therapies. Curr Opin Infect Dis 2000; 13:631-5.
46. Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-92.
47. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315:1151-4.
48. Cahn P, Vibhagool A, Schechter M, et al. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Curr Med Res Opin 2004; 20:1115-23.
49. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther 2004; 2:671-84.
50. Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9:291-6.